OKYO Pharma Announces Participation in May 2024 Investor Conferences
08 May 2024
Phase 2
OKYO Pharma Announces Participation in May 2024 Investor Conferences
LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced upcoming presentations at two investor conferences in May 2024.
Conference: Aegis Capital Virtual Healthcare Conference
Date: Wednesday May 8, 2024, 11 AM EST
Location: Virtual
Presenter: Gary Jacob, PhD, Chief Executive Officer
Conference: Citizens JMP Securities Life Sciences Conference
Date: Monday May 13, 2024, 10:30 AM EST
Location: New York, NY
Presenter: Gary Jacob, PhD, Chief Executive Officer
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
Enquiries:
OKYO Pharma LimitedGary S. Jacob, Chief Executive Officer917-497-7560Business Development & Investor RelationsPaul Spencer+44 (0)20 7495 2379
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.